Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bio-IT World September 2005 John Russell	BioSeek's MAP to Discovery Now, after roughly five years of platform development and building a database of assays, BioSeek seems poised for growth.
Chemistry World May 31, 2009 Nina Notman	The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used.
Chemistry World March 26, 2014 Phillip Broadwith	AstraZeneca boosts open innovation efforts Astrazeneca has launched a new web portal, bringing together new and existing open innovation programs. The aim is to make collaboration with academics, other companies, governments and non-government organizations easier.
Chemistry World November 2009 Derek Lowe	Column: In the pipeline The author advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World October 28, 2014 Derek Lowe	Chemical space is big. Really big. We are not going to run out of interesting and useful structures, and the uses that they could be put to are probably also beyond our imagining. In chemical space, we really do have an effectively endless frontier.
Chemistry World December 19, 2011 Rebecca Trager	US agencies collaborate to test 10,000 chemicals A high-speed robotic screening system jointly initiated by three key US health agencies began testing more than 10,000 chemical compounds for potential toxicity on 7 December.
Chemistry World May 2010 Derek Lowe	Column: In the pipeline The author wonders whether tagging molecules with fluorescent labels for assay is like tracking the members of a shoal of fish by tying each one to a whale. In the pharmaceutical business, our work absolutely lives and dies by assay results.
Reactive Reports Issue 41 David Bradley	Chip Chops Time off Drug Discovery Process A next-generation optical screening platform can screen a vast number of compounds rapidly by passing wave after wave of compounds in solution over the surface of the biochip.
The Motley Fool March 17, 2008 Brian Orelli	Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis...
Chemistry World July 26, 2012 Derek Lowe	Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time.
The Motley Fool November 3, 2009 Brian Orelli	Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend.
Bio-IT World February 10, 2003 Malorye Branca	Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.
Chemistry World December 10, 2014	Big pharma opens up abandoned drugs Sixty eight stalled pharmaceutical compounds are being made available for academic research through the UK Medical Research Council.
Chemistry World January 20, 2014 David Bradley	Molecular librarians create druglike collections Finding biologically active small molecules with pharmaceutical potential is a bittersweet process. Now, a new approach to building libraries of diverse alkaloid-type structures has been developed by US chemists.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
The Motley Fool November 9, 2011 Brian Orelli	Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it
Bio-IT World June 17, 2004 John Garvey	Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies.
The Motley Fool January 28, 2010 Brian Orelli	The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends.
The Motley Fool June 23, 2006 Stephen D. Simpson	Neurocrine Biosciences: From Bad to Worse Pfizer's departure is a serious, though not fatal, blow to the biotech. While this story may yet have a happy ending, there's going to be a lot of nervous waiting between now and then. Investors, take note.
Chemistry World August 2009 Derek Lowe	Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder
Chemistry World November 2011 Derek Lowe	Column: In the Pipeline In recent years there's another class of 'unknown' compounds that's become more prominent than ever: the ones you can buy from the chemical catalogues.
The Motley Fool May 29, 2008 Brian Lawler	Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing.
The Motley Fool November 16, 2007 Brian Orelli	Weighing In on Amylin's Drug Combination Phase 2 results are good for Amylin Pharmaceuticals trial of a new weight-loss treatment, but it's the subsequent phase 3 trial that actually counts.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
Food Processing March 2009 Diane Toops	Kraft Foods Global Thinks Outside the Box with Bioactive Ingredients Kraft hires a pharmaceutical company to help it develop functional foods.
Chemistry World July 3, 2012 Andrew Turley	BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs.
The Motley Fool August 17, 2010 Travers & Jayson	How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big.
The Motley Fool January 31, 2007 Brian Lawler	No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note.
The Motley Fool May 16, 2011 Brian Orelli	Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly.
The Motley Fool May 26, 2011 Brian Orelli	Amylin Scores First in Court But it is still early innings.
The Motley Fool February 24, 2010 Brian Orelli	A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year.
The Motley Fool October 20, 2011 Travis Hoium	Amylin Pharmaceuticals Shares Jumped: What You Need to Know Shares of Amylin Pharmaceuticals jumped 11% today after the company released great earnings and pipeline news.
The Motley Fool August 23, 2005 Stephen D. Simpson	A Cure for Amylin's Stock? Shares moved up after promising results from a diabetes-drug test. But will the gains last?
Information Today June 25, 2012	Penguin Group Launches Library Lending Pilot Program Penguin Group, The New York Public Library, and 3M Library Systems announced a pilot project that will make Penguin eBooks available to patrons of both The New York Public Library and the Brooklyn Public Library.
Chemistry World September 7, 2014 Michael Gross	Bringing chemical synthesis to the masses The promise of a novel approach to building chemical libraries, which only requires simple building blocks in water, without any additional reagents or sample preparation, is inspired by nature.
Chemistry World February 22, 2011 Amaya Camara-Campos	Repairing faulty genes Israeli scientists have developed compounds that could be better treatments for genetic diseases than current drugs.
Chemistry World January 3, 2012 Simon Hadlington	One-pot synthesis creates anticancer candidates Researchers in Germany have developed a simple, rapid and high-yielding cascade synthesis of a collection of polycyclic compounds that resemble indole alkaloid natural products and which interfere with cell division.
Information Today March 12, 2012	3M Cloud Library Announces Integration With Polaris ILS The 3M Cloud Library eBook Lending Service will now be integrated with the Polaris Integrated Library System, allowing patrons at participating libraries to discover both physical and digital collections from wherever they are browsing.
Bio-IT World June 17, 2004 Hope Melville	Is It Safe? Think the safe harbor provision in patent law lets you use patented compounds in all preclinical-phase research? Think again.
Chemistry World June 18, 2015 Emma Stoye	Crowdsourcing compounds to tackle antibiotic resistance Chemists around the world are being called on to donate samples of novel compounds they have synthesized to a crowdsourcing project that aims to find new antibiotics.
Information Today June 27, 2011 Barbara Quint	The British Library Joins Google Books Google Books continues its march through the national libraries of Europe with the announcement of a deal with the British Library.
The Motley Fool March 3, 2011 Brian D. Pacampara	Amylin Pharmaceuticals Shares Plunged: What You Need to Know Shares of Amylin Pharmaceuticals plummeted more than 20% Thursday after its type 2 diabetes drug Bydureon failed to meet primary endpoints in a 26-week study.
Information Today August 18, 2008	WebJunction Launches New Social Learning Site OCLC announced that WebJunction, the online learning community for librarians and library staff, has launched a new social and learning experience
The Motley Fool March 17, 2011 Brian Orelli	Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
Bio-IT World December 15, 2003 Malorye A. Branca	Scenes from a Cell Breakthroughs are making cell-based screening faster, easier, more powerful.
The Motley Fool January 27, 2011 Brian Orelli	Amylin Timeline Shortened -- Maybe Revenue down 6% year over year. Prescriptions of the company's top-selling drug, Byetta, down 5.9% quarter over quarter. Amylin Pharmaceuticals' fourth quarter wasn't pretty.
Chemistry World June 1, 2012 Derek Lowe	Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that.